Golidocitinib not checked

Dizal Pharmaceuticals · AZD4205

FollowEvery change as it happens, and a Monday email
Next date
Phase 3 trial completes
Trials
2 active
6 in total
Targets
—
None known yet

What this is

How it works
Blocks JAK enzymes that pass on immune signals, to calm an overactive immune system.-citinib: Janus kinase inhibitors WHO name stem
How it’s given
“150 mg, orally, once daily, with or without food, in a 21-day cycle”In the company’s words, NCT07234162 on ClinicalTrials.gov
Tested for
Peripheral T-cell Lymphoma, T-cell Lymphomas
Main trialPhase 3
“This is a phase 3, open-label, randomized, multinational study to evaluate the anti-tumor efficacy of golidocitinib versus investigator's choice in adult patients with relapsed/refractory peripheral T-cell lymphoma (r/r PTCL). This study will treat patients with pathologically confirmed PTCL who have relapsed after or been refractory/intolerant to at least one prior systemic treatment regimen(s).”In the company’s words, NCT07234162 on ClinicalTrials.gov
Other names
AZD4205

Other drugs for Peripheral T-cell Lymphoma

All 34 drugs for Peripheral T-cell Lymphoma

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials6

TrialPhaseCompletesWhat it tests
Phase 3Recruiting 30 Nov 2027 A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)
Phase 1/2Recruiting Sep 2029 Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)
Phase 2Completed 31 Mar 2025 AZD4205 in Peripheral T Cell Lymphoma Following First-Line Therapy (JACKPOT26)
Phase 2Completed 17 Oct 2025 AZD4205 in Relapsed or Refractory Peripheral T Cell Lymphoma (JACKPOT27)
Phase 1/2Completed 12 Oct 2023 Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8)
Phase 1Completed 8 Oct 2022 Drug-drug Interactions Between AZD4205 and Itraconazole/Carbamazepine
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Golidocitinib

Following is part of Solo: you see every change to Golidocitinib the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in